Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Public ClinicalTrials.gov record NCT05565417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009
Study identification
- NCT ID
- NCT05565417
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 67 participants
Conditions and interventions
Conditions
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Cutaneous Squamous Cell Carcinoma
- Hormone Receptor Positive Breast Carcinoma
- Small Bowel Cancer
- Esophageal Cancer
- Colorectal Cancer
- Diffuse Large B Cell Lymphoma
- Hodgkin Lymphoma
- Burkitt Lymphoma
- Follicular Lymphoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2022 (Actual)
- Primary completion
- Jan 2026 (Estimated)
- Completion
- Jan 2026 (Estimated)
- Last update posted
- Oct 16, 2025
2022 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 9618 | Tucson | Arizona | 85711 | — |
| Site 5000 | Denver | Colorado | 80218 | — |
| Site 4100 | Orlando | Florida | 32827 | — |
| Site 4060 | Sarasota | Florida | 34232 | — |
| Site 4500 | Oklahoma City | Oklahoma | 73104 | — |
| Site 9280 | Portland | Oregon | 97239 | — |
| Site 3000 | Nashville | Tennessee | 37203 | — |
| Site 9384 | Austin | Texas | 78705 | — |
| Site 9112 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05565417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05565417 live on ClinicalTrials.gov.